PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27124646-2	2016	Curcumin is a potential anticancer agent with p-glycoprotein (p-gp) inhibiting activity may be co-administered with docetaxel as a nanosuspension to enhance its anticancer effect by increasing the oral bioavailability and decreasing drug efflux.	Curcumin	0-8	phosphoglycolate phosphatase	Mus musculus	46-60	
18006147-3	2008	Here, we demonstrate that curcumin down-regulates P-gp expression in multidrug-resistant L1210/Adr cells.	Curcumin	26-34	phosphoglycolate phosphatase	Mus musculus	50-54	
18006147-7	2008	Thus, curcumin can contribute to the reversal of the MDR phenotype, probably due to the suppression of P-gp expression via the inhibition of the PI3K/Akt/NF-kappa B signaling pathway.	Curcumin	6-14	phosphoglycolate phosphatase	Mus musculus	103-107	
27124646-2	2016	Curcumin is a potential anticancer agent with p-glycoprotein (p-gp) inhibiting activity may be co-administered with docetaxel as a nanosuspension to enhance its anticancer effect by increasing the oral bioavailability and decreasing drug efflux.	Curcumin	0-8	phosphoglycolate phosphatase	Mus musculus	62-66	
27124646-10	2016	CONCLUSIONS: The in vitro and in vivo study of the nanosuspensions has shown that Co-administration of Curcumin as a p-gp inhibitor with docetaxel may have the potential to increase the anti-breast cancer efficacy of both drugs.	Curcumin	103-111	phosphoglycolate phosphatase	Mus musculus	117-121